JESÚS FERNANDO
SAN MIGUEL IZQUIERDO
Investigador en el periodo 1986-2013
Mayo Clinic
Rochester, Estados UnidosPublicaciones en colaboración con investigadores/as de Mayo Clinic (28)
2023
-
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group
The Lancet. Oncology, Vol. 24, Núm. 7, pp. e293-e311
2022
-
Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
Blood, Vol. 139, Núm. 4, pp. 492-501
-
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
Blood, Vol. 140, Núm. 11, pp. 1229-1253
2021
-
Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage
Blood Cancer Journal, Vol. 11, Núm. 12
-
Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group
The Lancet Oncology, Vol. 22, Núm. 3, pp. e119-e130
-
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
The Lancet Oncology, Vol. 22, Núm. 3, pp. e105-e118
2020
-
Clinical features associated with COVID-19 outcome in multiple myeloma: First results from the International Myeloma Society data set
Blood, Vol. 136, Núm. 26, pp. 3033-3040
-
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)
Blood Cancer Journal, Vol. 10, Núm. 10
2019
-
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
The Lancet, Vol. 394, Núm. 10214, pp. 2096-2107
-
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
The Lancet, Vol. 393, Núm. 10168, pp. 253-264
2018
-
Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials
Hematological Oncology, Vol. 36, Núm. 2, pp. 463-470
2015
-
Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma
New England Journal of Medicine, Vol. 372, Núm. 2, pp. 142-152
2014
-
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation
Journal of Clinical Oncology, Vol. 32, Núm. 6, pp. 587-600
-
Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma
Hematology/Oncology Clinics of North America, Vol. 28, Núm. 5, pp. 775-790
2013
-
Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma
Blood, Vol. 121, Núm. 6, pp. 884-892
-
Plasma cell leukemia: Consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group
Leukemia, Vol. 27, Núm. 4, pp. 780-791
2011
-
Consensus recommendations for risk stratification in multiple myeloma: Report of the International Myeloma Workshop Consensus Panel 2
Blood
-
Consensus recommendations for standard investigative workup: Report of the International Myeloma Workshop Consensus Panel 3
Blood
-
Consensus recommendations for the uniform reporting of clinical trials: Report of the International Myeloma Workshop Consensus Panel 1
Blood
-
Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone
Clinical Lymphoma, Myeloma and Leukemia, Vol. 11, Núm. 1, pp. 38-43